Clinical Trials with Mistletoe Extract ( Iscador® ) at the IKF Berlin

1. CURRENT PROJECTS
   1. Mistletoe Therapy for Advanced Pancreatic Cancer. A Group Sequential, Randomised, Open Label Study: in cooperation with Clinical Centers of Serbia/ Croatia (CCS and associated centers)
      (27-03)
      
   2. Randomized, open-label study on post-relapse disease-free survival (PRDFS) with the Viscum-album Extract (VA-E) Iscador P or oral Etoposide in spindle-cell bone-sarcoma patients in complete remission after surgery for second relapse (26-01)
      
   3. Pilot study with the mistletoe extract Iscador Qu spezial (instillation) in the treatment of bladder cancer (26-02)
      
      
2. COMPLETED PROJECTS
   
   1. Prospective, randomized, open-label phase-2 study to determine the immunomodulating and anti-HIV activities of the mistletoe extract Iscador QuFrF in HIV-positive patients (95-01)
      
   2. Prospective, non-radomized phase-2 study with matched-pair design to determine the preventive immunomodulating and cancer-inhibiting effects of the mistletoe extract Iscador Qu Spezial in patients with cervical dysplasia (95-02)
      
   3. Dose-escalating, open-label, non-randomized study to determine immunimodulating effects of Iscador QuFrF in healthy volunteers, in cancer patients and in HIV-positive patients (95-06)
      
   4. Prospective, randomized, open-label phase-II-trial to document immunomodulating and anti-HIV activities of Iscador QuFrF in combination with AZT + 3TC compared to AZT + 3TC alone in HIV-positives (97-01)
      
   5. Prospective, randomized, multi-centered, double-blind, placebo-controlled phase-3 trial with Iscador QuFrF in HIV-positives over an eighteen months period (97-02)
      
   6. Prospective, randomized, open-label phase-2 study to determine the preventive, immunomudulating and cancer-inhibiting effects of the misteltoe extract Iscador Qu Spezial in patients with cervical dysplasia (98-01)
      
   7. Prospective, non-randomized, open-label study to investigate the modulation of surgery-induced immunosuppression by peri-operative infusion of the mistletoe extract Iscador M Spezial (98-02)
      
   8. Prospective, randomized, single-blind study to investigate activation of homing-activities of T-lymphocytes by subcutaneous mistletoe extract injections in healthy male volunteers (98-06)
      
   9. Prospective pilot study to determine tolerability and effects of the misteltoe extract Iscador Qu Spezial in post-operative geriatric patients (20-05)
      
   10. Randomized, open-label phase-2 study to investigate the modulation of chemotherapy-induced immunosuppression by IV infusion of the mistletoe extract Iscador M Spezial (23-01)
   11. Randomized, open-label phase-2 study to investigate the adjuvant therapy of non-small cell lung cancer (NSCLC) stage IIIb/IV with the mistletoe extract Iscador Qu Spezial (23-07)